|
SOS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.30489996375394E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.293600002787E-09 |
| Normal-vs-Stage2 |
1.207180E-01 |
| Normal-vs-Stage3 |
2.86269999927313E-08 |
| Normal-vs-Stage4 |
1.05810005202045E-09 |
| Stage1-vs-Stage2 |
9.456400E-03 |
| Stage1-vs-Stage3 |
2.925600E-01 |
| Stage1-vs-Stage4 |
5.027800E-02 |
| Stage2-vs-Stage3 |
1.575360E-03 |
| Stage2-vs-Stage4 |
3.813300E-04 |
| Stage3-vs-Stage4 |
3.329200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.70229982624448E-10 |
| Normal-vs-AfricanAmerican |
1.298470E-02 |
| Normal-vs-Asian |
2.03010000032755E-07 |
| Caucasian-vs-AfricanAmerican |
1.343850E-01 |
| Caucasian-vs-Asian |
6.182000E-01 |
| AfricanAmerican-vs-Asian |
1.025360E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.39949999999889E-06 |
| Normal-vs-Female |
3.64620000858906E-09 |
| Male-vs-Female |
6.895600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.18690000447697E-08 |
| Normal-vs-Age(41-60Yrs) |
4.89920000124044E-08 |
| Normal-vs-Age(61-80Yrs) |
1.62167999999685E-05 |
| Normal-vs-Age(81-100Yrs) |
5.399100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.554600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.955200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.185800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.763200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.073000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.819000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.017600E-01 |
| Classical-VS-Follicular |
4.664400E-03 |
| Classical-VS-Other |
6.848400E-01 |
| Classical-VS-Normal |
1.27809995920103E-09 |
| Tall-VS-Follicular |
4.019200E-03 |
| Tall-VS-Other |
9.800400E-01 |
| Tall-VS-Normal |
1.1948999999456E-06 |
| Follicular-VS-Other |
2.243200E-01 |
| Follicular-VS-Normal |
1.727650E-02 |
| Other-VS-Normal |
7.418300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.82379999955774E-07 |
| Normal-vs-N1 |
6.93250001848611E-09 |
| N0-vs-N1 |
6.811900E-02 |
|
|
